- Home
- ELVN
as of 02-24-2026 9:37am EST
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | BOULDER |
| Market Cap: | 1.1B | IPO Year: | 2020 |
| Target Price: | $41.00 | AVG Volume (30 days): | 683.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.35 | EPS Growth: | 5.97 |
| 52 Week Low/High: | $13.30 - $30.22 | Next Earning Date: | 01-01-0001 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -20.30 | Index: | N/A |
| Free Cash Flow: | -73236000.0 | FCF Growth: | N/A |
Stock Insider Trading Activity of Enliven Therapeutics Inc. (ELVN)
Director
Avg Cost/Share
$26.18
Shares
1,230
Total Value
$32,196.36
Owned After
22,647
SEC Form 4
CHIEF MEDICAL OFFICER
Avg Cost/Share
$26.17
Shares
45,000
Total Value
$1,177,861.50
Owned After
25,000
SEC Form 4
CHIEF SCIENTIFIC OFFICER
Avg Cost/Share
$29.04
Shares
5,000
Total Value
$145,219.00
Owned After
740,188
SEC Form 4
CHIEF SCIENTIFIC OFFICER
Avg Cost/Share
$26.64
Shares
20,000
Total Value
$535,098.99
Owned After
740,188
Director
Avg Cost/Share
$26.71
Shares
1,230
Total Value
$32,901.52
Owned After
22,647
CHIEF OPERATING OFFICER
Avg Cost/Share
$28.24
Shares
48,300
Total Value
$1,351,762.20
Owned After
215,011
CHIEF SCIENTIFIC OFFICER
Avg Cost/Share
$27.02
Shares
91,198
Total Value
$2,482,578.16
Owned After
740,188
Director
Avg Cost/Share
$25.00
Shares
4,285
Total Value
$107,125.43
Owned After
22,647
SEC Form 4
CHIEF SCIENTIFIC OFFICER
Avg Cost/Share
$22.53
Shares
41,302
Total Value
$993,435.79
Owned After
740,188
Director
Avg Cost/Share
$25.02
Shares
9,635
Total Value
$241,155.53
Owned After
22,647
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Heyman Richard A. | ELVN | Director | Feb 17, 2026 | Sell | $26.18 | 1,230 | $32,196.36 | 22,647 | |
| Collins Helen Louise | ELVN | CHIEF MEDICAL OFFICER | Feb 17, 2026 | Sell | $26.17 | 45,000 | $1,177,861.50 | 25,000 | |
| Lyssikatos Joseph P | ELVN | CHIEF SCIENTIFIC OFFICER | Feb 6, 2026 | Sell | $29.04 | 5,000 | $145,219.00 | 740,188 | |
| Lyssikatos Joseph P | ELVN | CHIEF SCIENTIFIC OFFICER | Jan 20, 2026 | Sell | $26.64 | 20,000 | $535,098.99 | 740,188 | |
| Heyman Richard A. | ELVN | Director | Jan 20, 2026 | Sell | $26.71 | 1,230 | $32,901.52 | 22,647 | |
| Patel Anish | ELVN | CHIEF OPERATING OFFICER | Jan 9, 2026 | Sell | $28.24 | 48,300 | $1,351,762.20 | 215,011 | |
| Lyssikatos Joseph P | ELVN | CHIEF SCIENTIFIC OFFICER | Jan 9, 2026 | Sell | $27.02 | 91,198 | $2,482,578.16 | 740,188 | |
| Heyman Richard A. | ELVN | Director | Jan 9, 2026 | Sell | $25.00 | 4,285 | $107,125.43 | 22,647 | |
| Lyssikatos Joseph P | ELVN | CHIEF SCIENTIFIC OFFICER | Jan 8, 2026 | Sell | $22.53 | 41,302 | $993,435.79 | 740,188 | |
| Heyman Richard A. | ELVN | Director | Jan 8, 2026 | Sell | $25.02 | 9,635 | $241,155.53 | 22,647 |
Compare ELVN vs Leading Stocks
See how ELVN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ELVN Enliven Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.